MADELAIN, V.; MENTRE, F.; BAIZE, S.; ANGLARET, Xavier; LAOUENAN, C.; OESTEREICH, L.; NGUYEN, T. H. T.; MALVY, Denis; PIORKOWSKI, G.; GRAW, F.; GUNTHER, S.; RAOUL, H.; DE LAMBALLERIE, X.; GUEDJ, J.

doi:10.1002/psp4.12510

Langue

Article de revue

Ce document a été publié dans

CPT: Pharmacometrics and Systems Pharmacology. 2020

Résumé en anglais

In 2014, our research network was involved in the evaluation of favipiravir, an anti‐influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.< Réduire

Mots clés

IDLIC

URI

https://oskar-bordeaux.fr/handle/20.500.12278/26134

DOI

http://dx.doi.org/10.1002/psp4.12510

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés

URI

DOI

Unités de recherche